Neuromuscular

FDA Accepts Application for Genetic Treatment of Spinal Muscular Atrophy Type 1

Wednesday, December 05, 2018—The Food and Drug Administration (FDA) has accepted the Biologics License Application for onasemnogene abeparvovec-xxxx (AVXS-101, Zolgensma; AveXis, Bannockburn, Illinoi…

Dystonia and Spasticity Patients May Become Immune to Toxin Treatment

Tuesday, December 04, 2018—People with dystonia or spasticity can get relief from botulinum toxin type A, but a new study published online in Neurology shows that 15% of people treated with th…

FDA Approves Amifampridine for Lambert-Eaton Myasthenic Syndrome

Monday, December 03, 2018—The FDA has approved amifampridine (Firdapse, Catalyst Pharmaceuticals, Coral Gables, FL) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. This…

Hometown Highlights: Clinical Experience Treating Adults With Spinal Muscular Atrophy

Lauren Elman, MD

November/December 2018—Treating adult patients with antisense oligonucleotide therapy proven effective in children presents unique challenges.

Treating Stress to Improve Neurologic Outcomes

Graham R. Huesmann, MD, PhD; and Riley Bove, MD

November/December 2018—Research on the interaction between hormones and seizures supports the importance of helping patients manage stress.

Healthy Cognitive Aging

Elizabeth Londen, PhD; Thomas Preston, PhD, ABBP-CN; and Brian K. Lebowitz, PhD, ABBP-CN

November/December 2018—There are evidence-based tools for staying sharp throughout the lifespan.

Moving the Mouse With the Mind

With Leigh R. Hochberg, MD, PhD

November/December 2018—Braingate technology allows patients with tetrapalegia to move a computer cursor by thinking about it.

Video-Case Report: Progressive Neuropathy With Cerebellar Ataxia

Asseel Albayati, MD; Safa AlJammali, MD; Mohammed AlKhero, MD; and Aziz Shaibani, MD

November/December 2018—Investigation of antibody titers is essential for patients who have neuropathy with cerebellar ataxia and do not respond to IVIG treatment.